Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Janux Therapeutics Inc (NQ: JANX )

58.09 -1.52 (-2.54%)
Streaming Delayed Price Updated: 1:56 PM EST, Dec 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Janux Therapeutics Inc

< Previous 1 2 3 4 Next >
Navigating 10 Analyst Ratings For Janux Therapeutics
Via Benzinga
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks. 
Via Benzinga
Why Janux Therapeutics Crushed the Market Today
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
S&P 500 Cools From Post-Election Record Highs
The Dow Jones Industrial Average is down triple digits this afternoon, as traders unpack this morning's jobs data. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics
Via Benzinga
Navigating 5 Analyst Ratings For Janux Therapeutics
Via Benzinga
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
Janux Therapeutics reports updated clinical data for JANX007, highlighting significant efficacy, safety, and durability in advanced prostate cancer patients. 
Via Benzinga
AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels. 
Via Investor's Business Daily
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Analyst Expectations For Janux Therapeutics's Future
Via Benzinga
The Latest Analyst Ratings For Janux Therapeutics
Via Benzinga
Analyst Ratings For Janux Therapeutics
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts
Via Benzinga
Why Janux Therapeutics Stock Is Crushing It This Week
Janux's silence about a potential acquisition deal could be golden. 
Via The Motley Fool
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
Although fraught with risk, these biotech exposures bring enormous upside potential. 
Via Talk Markets
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
Via Benzinga
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Take the Money and Run: 3 Overbought Stocks to Sell ASAP
Although speculators were smart enough to jump on these ideas, they’re currently overbought stocks that may require trimming. 
Via InvestorPlace
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank? 
Via InvestorPlace
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. 
Via Benzinga
Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?
Janux Therapeutics may be up for sale amid interest from major pharmaceutical firms. With shares quadrupling this year and a successful equity offering, Janux is making waves in the industry. The... 
Via Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.